<DOC>
	<DOCNO>NCT00191152</DOCNO>
	<brief_summary>This phase III randomize study docetaxel/gemcitabine docetaxel/ capecitabine doublet , crossover alternate agent . The experimental arm receive gemcitabine 1000 mg/m2 intravenous ( IV ) 30 minute day 1 8 docetaxel 75 mg/m2 IV day 1 1 hour repeat every three week . The comparator arm receive docetaxel 75 mgm/m2 IV day 1 1 hour oral capecitabine 1000 mg/m2 twice daily , day 1 14 repeat every three week . Patients progress experimental arm , treat capecitabine dose comparator arm . Patients progress comparator arm treat gemcitabine dose experimental arm .</brief_summary>
	<brief_title>A Phase III Trial For Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologic cytologic confirmation breast cancer locally advance and/or metastatic disease Patients may receive prior neoadjuvant adjuvant taxane regimen long great equal 6 month since completion regimen Patients may 01 , one prior course chemotherapy metastatic disease Patients must either measurable nonmeasurable ( evaluable ) disease Prior radiation therapy allow less 25 % bone marrow Second primary malignancy ( except situ carcinoma cervix adequately treat nonmelanomatous carcinoma skin malignancy treat least 5 year previously evidence recurrence ) Parenchymal leptomeningeal brain metastases Peripheral neuropathy great equal grade 2 Prior treatment gemcitabine capecitabine allow . Prior treatment taxane metastatic setting allow . Prior taxane therapy neoadjuvant adjuvant setting allow completion therapy great equal 6 month prior enrollment . Active cardiac disease control therapy and/or myocardial infarction within precede 6 month . Concomitant Herceptin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>